These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26046338)

  • 61. What does the PANSS mean?
    Leucht S; Kane JM; Kissling W; Hamann J; Etschel E; Engel RR
    Schizophr Res; 2005 Nov; 79(2-3):231-8. PubMed ID: 15982856
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response.
    Leucht S; Chaimani A; Leucht C; Huhn M; Mavridis D; Helfer B; Samara M; Cipriani A; Geddes JR; Salanti G; Davis JM
    Schizophr Res; 2018 Nov; 201():315-323. PubMed ID: 29804928
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The PANSS should be rescaled.
    Leucht S; Kissling W; Davis JM
    Schizophr Bull; 2010 May; 36(3):461-2. PubMed ID: 20357133
    [No Abstract]   [Full Text] [Related]  

  • 64. Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.
    Subeesh V; Maheswari E; Singh H; Saraswathy GR; Reddy N; Chiranjeevi P
    Int J Psychiatry Clin Pract; 2020 Sep; 24(3):309-314. PubMed ID: 32338556
    [No Abstract]   [Full Text] [Related]  

  • 65. Symptomatic response to antipsychotics differs between recent onset and recurrent chronic schizophrenic patients.
    Hill C; Keks NA; Jackson H; Kulkarni J; Hannah D; Copolov D; Singh B
    Aust N Z J Psychiatry; 1992 Sep; 26(3):417-22. PubMed ID: 1358053
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association of Positive and Negative Syndrome Scale short forms with global functioning and quality of life.
    Hochstrasser L; Borgwardt S; Lambert M; Schimmelmann BG; Lang UE; Stieglitz RD; Huber CG
    Acta Psychiatr Scand; 2016 Dec; 134(6):563-565. PubMed ID: 27869990
    [No Abstract]   [Full Text] [Related]  

  • 67. The SWITCH study: rationale and design of the trial.
    Heres S; Cirjaliu DM; Dehelean L; Matei VP; Podea DM; Sima D; Stecher L; Leucht S
    Eur Arch Psychiatry Clin Neurosci; 2016 Sep; 266(6):513-21. PubMed ID: 26227799
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications.
    Takeuchi H; Sanches M; Borlido C; Agid O; Remington G
    Schizophr Res; 2021 Nov; 237():202-207. PubMed ID: 34563881
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia.
    Ji S; Li A; Wu K; Deng C; Dong F; Li L; Zhou T; Yue W; Wang CY; Lu W
    Pharmacopsychiatry; 2016 May; 49(3):117-23. PubMed ID: 26808834
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Should the PANSS be rescaled?
    Obermeier M; Mayr A; Schennach-Wolff R; Seemüller F; Möller HJ; Riedel M
    Schizophr Bull; 2010 May; 36(3):455-60. PubMed ID: 19889950
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A clinimetric analysis of a BPRS-6 scale for schizophrenia severity.
    Bech P; Austin SF; Timmerby N; Ban TA; Møller SB
    Acta Neuropsychiatr; 2018 Aug; 30(4):187-191. PubMed ID: 29409548
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study.
    Hajj A; Obeid S; Sahyoun S; Haddad C; Azar J; Rabbaa Khabbaz L; Hallit S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557839
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A systematic review of the operational definitions for antipsychotic response in delusional disorder.
    González-Rodríguez A; Estrada F; Monreal JA; Palao D; Labad J
    Int Clin Psychopharmacol; 2018 Sep; 33(5):261-267. PubMed ID: 29912058
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Meta-analytic exploration of the joint factors of the Brief Psychiatric Rating Scale - Expanded (BPRS-E) and the positive and negative symptoms scales (PANSS).
    Shafer A; Dazzi F
    J Psychiatr Res; 2021 Jun; 138():519-527. PubMed ID: 33979704
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A novel approach to measuring response and remission in schizophrenia in clinical trials.
    Aboraya A; Leucht S; Nasrallah HA; Samara M; Haro JM; Elshazly A; Zangeneh M
    Schizophr Res; 2017 Dec; 190():123-128. PubMed ID: 28314680
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Patients' subjective rating of mental health improvement in a randomised controlled trial.
    Hayhurst KP; Drake RJ; Massie JA; Dunn G; Lewis SW
    Psychiatry Res; 2015 Sep; 229(1-2):593-5. PubMed ID: 26208989
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia.
    Ohnishi T; Wakamatsu A; Kobayashi H
    Neuropsychiatr Dis Treat; 2021; 17():1095-1104. PubMed ID: 33888985
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Correlation analysis between antipsychotic prescription quality and clinical status of patients with schizophrenia].
    Martínez Granados F; Moñino Martínez C; Pol Yanguas E; Ivorra Cano JM; Villar Malpica JL
    Farm Hosp; 2005 Mar; 29(2):95-103. PubMed ID: 16013931
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early prediction of blonanserin response in Japanese patients with schizophrenia.
    Kishi T; Matsuda Y; Fujita K; Iwata N
    Neuropsychiatr Dis Treat; 2014; 10():1861-6. PubMed ID: 25285009
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cannabis use the week before admission to psychiatric in-patient service as a marker of severity.
    Madero S; Oliveras C; Pons MT; Sague M; López-Pelayo H; Gual A; Balcells M
    J Psychiatr Res; 2020 Oct; 129():40-46. PubMed ID: 32563776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.